Ph.D., 2009, University of Toronto, Canada
Cancer is a very difficult disease to fight because the immune system has trouble recognizing it. However, cancer cells different dramatically from normal cells in their cell metabolism. My research aims at identifying metabolic enzymes and signaling pathways that provide the most attractive intervention points for treating cancer. Armed with such valuable knowledge, I am also trying to tackle these signaling pathways by screening chemical compounds in search of potential inhibitors that could lead to a new class of cancer treatments.
Zhang Y, Kozlov G, Pocanschi C, Brockmeier U, Ireland BS, Maattanen P, Howe C, Elliott T, Gehring K, Williams DB. ERp57 does not require interactions with calnexin and calreticulin to promote assembly of class I histocompatibility molecules and it enhances peptide loading independently of its redox activity. J Biol Chem. 2009 Apr 10; 284 (15): 10160-73.
Zhang Y, Williams DB. Assembly of MHC class I molecules within the endoplasmic reticulum. Immunol Res. 2006; 35 (1-2): 151-62.
Zhang Y, Baig E, Williams DB. Functions of ERp57 in the folding and assembly of major histocompatibility complex class I molecules. J Biol Chem. 2006 May 26; 281 (21): 14622-31.
Hu K, Sun Y, Chen D, Zhang Y. The effect of lipid environment in purple membrane on bacteriorhodopsin. J Photochem Photobiol B. 2000 Nov; 58 (2-3): 163-9.
Zhang Y, Yang G, Hu K. The conformational and functional effect of biotin modification on purple membrane. ACTA Biophysica Sinica. 2000 16 (4): 797-800.